Innovation Tops the BMS (Taiwan) Agenda
During its 52 years of doing business in Taiwan, Bristol-Myers Squibb (BMS) has spearheaded the introduction into this market of cutting-edge medicines for the treatment of serious ailments such as hepatitis B and C, rheumatoid arthritis and other immune related diseases, and leukemia and other types of cancer. The parent company is the result of…